Welcome to the Emerging Pathogens & Infectious Diseases Consortium
Welcome to EPIC – the Emerging Pathogens and Infectious Diseases Consortium.
EPIC brings together researchers, clinicians, and institutions across the University of Toronto and its hospital partners to advance infectious disease research and build lasting resilience against emerging threats.
This work builds on a long legacy: EPIC partners have played an integral role in infectious disease research for a century, from work that helped control diphtheria and eradicate smallpox, to today’s front-line research in antimicrobial resistance and infection control. Our collective response to COVID-19, highly pathogenic avian influenza, and mpox makes clear there’s never been a more important time to advance that work, from emerging pathogens and antimicrobial resistance to health inequities and public trust.
Building on this momentum, EPIC marshals the advanced research infrastructure and world-renowned research and training expertise of our EPIC partners to deliver an integrated, innovative response to the infectious disease challenges facing communities today and in the future.
Seven EPIC research clusters
Antimicrobial resistance
Protecting the effectiveness of the medicines we depend on.
Chronic infections and long-term sequelae
Addressing the long-term burden of infections that don’t resolve.
Emerging and re-emerging pathogens
Detecting and responding to new and re-emerging threats before they spread.
Health inequities
Ensuring infectious disease research and response reach everyone, equitably.
Health systems resilience
Building health systems that bend, not break, under infectious threats.
Misinformation, disinformation and public trust
Strengthening public trust through clear, credible information.
Sepsis and acute infections
Improving detection and treatment when every minute counts.
EPIC News
The Canada-Africa Mpox Partnership launches with $3 million team grant
Researchers from the University of Toronto and Nigerian Institute of Medical Research have received $3 million from the federal government to launch an international project that will help inform the clinical and public health response to local and global epidemic of mpox. The new funding from the Canadian Institutes of Health Research (CIHR) and International Development Research Centre builds on the collaborative projects and seed funding from the mpox rapid research response launched by EPIC earlier this year.
World AIDS Day: Meet the next generation of HIV/AIDS researchers
On World AIDS Day, we spotlight eight talented trainees who are doing impactful work on HIV/AIDS.
EPIC and bioMérieux bring leading researchers together for symposium on antimicrobial resistance
On November 23, the University of Toronto’s Emerging and Pandemic Infections Consortium (EPIC) partnered with diagnostics industry leader bioMérieux Canada to jointly host a research symposium on Canadian perspectives on antimicrobial resistance: where we are now and looking ahead.
